Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP878276.RAopNgDrdji64ssZFu1pWUufd9RuHZD3VAkd8s5L10i8Y130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP878276.RAopNgDrdji64ssZFu1pWUufd9RuHZD3VAkd8s5L10i8Y130_assertion type Assertion NP878276.RAopNgDrdji64ssZFu1pWUufd9RuHZD3VAkd8s5L10i8Y130_head.
- NP878276.RAopNgDrdji64ssZFu1pWUufd9RuHZD3VAkd8s5L10i8Y130_assertion description "[Treatment of metastatic disease has improved significantly with the addition of several new agents, including tyrosine kinase inhibitors, mammalian target of rapamycin inhibitors, and yttrium-90-DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) and lutetium-177-DOTA octreotate.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP878276.RAopNgDrdji64ssZFu1pWUufd9RuHZD3VAkd8s5L10i8Y130_provenance.
- NP878276.RAopNgDrdji64ssZFu1pWUufd9RuHZD3VAkd8s5L10i8Y130_assertion evidence source_evidence_literature NP878276.RAopNgDrdji64ssZFu1pWUufd9RuHZD3VAkd8s5L10i8Y130_provenance.
- NP878276.RAopNgDrdji64ssZFu1pWUufd9RuHZD3VAkd8s5L10i8Y130_assertion SIO_000772 21388967 NP878276.RAopNgDrdji64ssZFu1pWUufd9RuHZD3VAkd8s5L10i8Y130_provenance.
- NP878276.RAopNgDrdji64ssZFu1pWUufd9RuHZD3VAkd8s5L10i8Y130_assertion wasDerivedFrom befree-2016 NP878276.RAopNgDrdji64ssZFu1pWUufd9RuHZD3VAkd8s5L10i8Y130_provenance.
- NP878276.RAopNgDrdji64ssZFu1pWUufd9RuHZD3VAkd8s5L10i8Y130_assertion wasGeneratedBy ECO_0000203 NP878276.RAopNgDrdji64ssZFu1pWUufd9RuHZD3VAkd8s5L10i8Y130_provenance.